Dose-response relationship of ultrasound contrast agent in an in vivo murine melanoma model

Cancer Imaging

Volumn 7, Issue 1, 2007, Pages 216-223

  Seiler, Gabriela S ^a   Ziemer, Lisa S ^a,b   Schultz, Susan ^b   Lee, William M F ^b   Sehgal, Chandra M ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antivascular; Cancer; Contrast enhanced ultrasound; Dose; Melanoma; Mouse

Indexed keywords

ALBUMINOID; ANTINEOPLASTIC AGENT; COMBRETASTATIN A 4; COMBRETASTATIN A-4; CONTRAST MEDIUM; FLUOROCARBON; PERFLUTREN; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; COMPARATIVE STUDY; DOPPLER FLOWMETRY; DOSE RESPONSE; ECHOGRAPHY; EXPERIMENTAL MELANOMA; IMAGE PROCESSING; MOUSE; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROCARBONS; IMAGE PROCESSING, COMPUTER-ASSISTED; MELANOMA, EXPERIMENTAL; MICE; NEOVASCULARIZATION, PATHOLOGIC; STILBENES; ULTRASONOGRAPHY, DOPPLER;

EID: 38449111806     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2007.0031     Document Type: Article

References (38)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. Nyberg P, Xie L, Kalluri R. 2 Endogenous inhibitors of angiogenesis. Cancer Res 2005; 65: 3967-79.
3. Cao Y. Antiangiogenic cancer therapy. Semin Cancer Biol 2004; 14: 139-45. (Pubitemid 38234756)
4. Tozer GM. Measuring tumour vascular response to antivascular and antiangiogenic drugs. Br J Radiol 2003; 76: S23-35. (Pubitemid 39530313)
5. Rehman S, Jayson GC. Molecular imaging of antiangiogenic agents. The Oncologist 2005; 10: 92-103. (Pubitemid 40261948)
6. Krix M, Kiessling F, Vosseler S, et al. Sensitive noninvasive monitoring of tumor perfusion during antiangiogenic therapy by intermittent bolus-contrast power Doppler sonography. Cancer Res 2003; 63: 8264-70. (Pubitemid 37549477)
7. Ferrara KW, Merritt CR, Burns PN, Foster FS, Mattrey RF, Wickline SA. Evaluation of tumor angiogenesis with US: imaging, Doppler and contrast agents. Acad Radiol 2000; 7: 824-39.
8. Iordanescu I, Becker C, Zetter B, Dunning P, Taylor GA. Tumor vascularity: evaluation in a murine model with contrast-enhanced color Doppler US - effect of angiogenesis inhibitors. Radiology 2002; 222: 460-7. (Pubitemid 34106120)
9. Bunte RM, Ansaloni S, Sehgal CM, Lee WM, Wood AK. Histopathological observations on the antivascular effects of physiotherapy ultrasound on a murine neoplasm. Ultrasound Med Biol 2006; 32: 453-61. (Pubitemid 43356733)
10. Ziemer LS, Lee WMF, Vinogradov SA, Sehgal CM, Wilson DF. Oxygen distribution in murine tumors: characterization using oxygen-dependent quenching of phosphorescence. J Appl Physiol 2005; 98: 1503-10. (Pubitemid 40396529)
11. Wood AK, Ansaloni S, Ziemer LS, Lee WM, Feldman MD, Sehgal CM. The antivascular action of physiotherapy ultrasound on murine tumors. Ultrasound Med Biol 2006; 32: 453-61.
12. Yankeelov TE, Niermann KJ, Huamani J, et al. Correlation between estimates of tumor perfusion from microbubble contrast-enhanced sonography and dynamic contrast-enhanced magnetic resonance imaging. J Ultrasound Med 2006; 25: 487-97.
13. Lucidarme O, Kono Y, Corbeil J, et al. Angiogenesis: noninvasive quantitative assessment with contrast-enhanced functional US in murine model. Radiology 2006; 239: 730-9. (Pubitemid 43830608)
14. Forsberg F, Ro RJ, Potoczek M, et al. Assessment of angiogenesis: implications for ultrasound imaging. Ultrasonics 2004; 42: 325-30.
15. Korpanty G, Carbon JG, Grayburn PA, Fleming JB, Brekken RA. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 2007; 13: 323-30. (Pubitemid 46121886)
16. Cuenod CA, Fournier L, Balvay D, Guinebretiere JM. Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment. Abdom Imaging 2006; 31: 188-93.
17. Kamotani Y, Lee WM, Arger PH, Cary TW, Sehgal CM. Multigated contrast-enhanced power Doppler to measure blood flow in mice tumors. Ultrasound Med Biol 2003; 29: 977-84. (Pubitemid 36871728)
18. Sehgal CM, Arger PH, Silver AC, et al. Renal blood flow changes induced with endothelin-1 and fenoldopam mesylate at quantitative Doppler US: initial results in a canine study. Radiology 2001; 219: 419-426. (Pubitemid 32336355)
19. Weinstein SP, Conant EF, Sehgal CM, Woo IP, Patton JA. Hormonal variations in the vascularity of breast tissue. J Ultrasound Med 2005; 24: 67-72. (Pubitemid 40039783)
20. Chomas JE, Pollard RE, Sadlowski AR, Griffey SM, Wisner ER Ferrara KW. Contrast-enhanced US of microcirculation of superficially implanted tumors in rats. Radiology 2003; 229: 439-46. (Pubitemid 37310831)
21. Fleischer AC, Donnelly EF, Grippo RJ, Black AS, Hallahan D. Quantification of tumor vascularity with contrast-enhanced Sonography. J Ultrasound Med 2004; 23: 37-41.
22. Carver BS, Pandolfi, PP. Mouse modelling in oncologicpreclinical and translational research. Clin Cancer Res 2006; 5305-11
23. Cespedes MV, Casanova I, Parreno M, Mangues R. Mousemodels in oncogenesis and cancer therapy. Clin Transi Oncol 8: 318-29.
24. Li P, Armstrong WF, Miller DL Impact of myocardial contrastechocardiography on vascular permeability: comparison of threedifferent contrast agents. Ultrasound Med Biol 2004; 30: 83-91
25. Miller DL, Quddus J. Diagnostic ultrasound activation of contrastagent gas bodies induces capillary rupture in mice. Proc Natl Acad Sci U S A 2000; 97: 10179-84.
26. Wu CY, Lo MT, Tsao J, Chu A, Chou YH, Tiu CM. Factoranalysis in both spatial and temporal domains of color bloomingartifacts in ultrasound investigations utilizing contrast agents. Comput Med Imaging Graphics 2004; 28: 129-40.
27. Forsberg F, Liu JB, Merton DA, Rawool NM, Goldberg BB. Parenchymal enhancement and tumor visualization using a new sonographic contrast agent. J Ultrasound Med 1995; 14: 949-57.
28. Pugh CR, Arger PH, Sehgal CM. Power, spectral and color flowDoppler enhancement by a new ultrasonographic contrast agent. J Ultrasound Med 1996; 15: 843-52.
29. Forsberg F, Liu JB, Burns PN. Artifacts in ultrasonic contrastagent studies. J Ultrasound Med 1994; 13: 357-65.
30. McCulloch M, Gresser C, Moos S, et al. Ultrasound contrastphysics: a series on contrast echocardiography, article 3. J AmSoc Echocardiogr 2000; 13: 959-67.
31. Masugata H, DeMaria AN, Peters B, et al Difference of optimal dose of contrast agent between grey-scale and power Doppler imaging in assessing graded coronary stenosis by myocardial contrast echocardiography. Invest Radiol 2003; 38: 550-8. (Pubitemid 37046500)
32. Gee MS, Koch CJ, Evans SM, et al Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Res 1999; 59; 4882-9. (Pubitemid 29472892)
33. Gee MS, Saunders HM, Lee JC, et al Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations. Cancer Res 2001; 61: 2974-82. (Pubitemid 32691943)
34. Tozer GM, Kanthou C, Baguley BC. Disrupting tumor blood vessels. Nature Reviews 2005; 5: 423-35.
35. Tozer GM. Measuring tumour vascular response to antivascular and antiangiogenic drugs. Br J Radiol 2003; 76 (spec no 1): S23-35. (Pubitemid 39530313)
36. Beauregard DA, Thelwall DE, Chaplin DJ, Hill SA, Adams GE, Brindle KM. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 1998; 77: 1761-7. (Pubitemid 28254609)
37. Sehgal CM, Arger PH. Mathematical modelling of the dilution curves for ultrasonographic contrast agents. J Ultrasound Med 1997; 16: 471-9. (Pubitemid 27391814)
38. Li J, Dong B, Yu X, Wang X, Li C. Grey-scale contrast enhancement in rabbit liver with Sonovue™ at different doses. Ultrasound Med Biol 2005; 31: 185-90. (Pubitemid 40228773)